ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000021

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Identifieur interne : 000021 ( PascalFrancis/Corpus ); précédent : 000020; suivant : 000022

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Auteurs : Kenneth Marek ; John Seibyl ; Shirley Eberly ; David Oakes ; Ira Shoulson ; Anthony E. Lang ; Chris Hyson ; Danna Jennings

Source :

Neurology [ 0028-3878 ] ; 2014.

RBID : Pascal:14-0154166

Descripteurs français

Pascal (Inist)
- Pathologie du système nerveux, Homme.

English descriptors

KwdEn :
- Human, Nervous system diseases.

Abstract

Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [¹²³|] β-CIT SPECT scans were acquired. The percent change in [¹²³|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [¹²³|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0028-3878`
A02	`01`			`@0 NEURAI`
A03		`1`		`@0 Neurology`
A05				`@2 82`
A06				`@2 20`
A08	`01`	`1`	`ENG`	`@1 Longitudinal follow-up of SWEDD subjects in the PRECEPT Study`
A11	`01`	`1`		`@1 MAREK (Kenneth)`
A11	`02`	`1`		`@1 SEIBYL (John)`
A11	`03`	`1`		`@1 EBERLY (Shirley)`
A11	`04`	`1`		`@1 OAKES (David)`
A11	`05`	`1`		`@1 SHOULSON (Ira)`
A11	`06`	`1`		`@1 LANG (Anthony E.)`
A11	`07`	`1`		`@1 HYSON (Chris)`
A11	`08`	`1`		`@1 JENNINGS (Danna)`
A14	`01`			`@1 Institute for Neurodegenerative Disorders @2 Rochester, NY @3 USA @Z 1 aut. @Z 2 aut. @Z 8 aut.`
A14	`02`			`@1 University of Rochester @2 Rochester, NY @3 USA @Z 3 aut. @Z 4 aut.`
A14	`03`			`@1 Georgetown University @2 Washington, DC @3 USA @Z 5 aut.`
A14	`04`			`@1 University of Toronto @2 London, Ontario @3 CAN @Z 6 aut.`
A14	`05`			`@1 Western University @2 London, Ontario @3 CAN @Z 7 aut.`
A17	`01`	`1`		`@1 The Parkinson Study Group PRECEPT Investigators @3 INC`
A20				`@1 1791-1797`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 6345 @5 354000502741180070`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 14-0154166`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neurology`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [¹²³\|] β-CIT SPECT scans were acquired. The percent change in [¹²³\|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [¹²³\|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B18D04B`
C03	`01`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 01`
C03	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 01`
C03	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 01`
C03	`02`	`X`	`FRE`	`@0 Homme @5 09`
C03	`02`	`X`	`ENG`	`@0 Human @5 09`
C03	`02`	`X`	`SPA`	`@0 Hombre @5 09`
N21				`@1 195`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0154166 INIST
ET :	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study
AU :	MAREK (Kenneth); SEIBYL (John); EBERLY (Shirley); OAKES (David); SHOULSON (Ira); LANG (Anthony E.); HYSON (Chris); JENNINGS (Danna)
AF :	Institute for Neurodegenerative Disorders/Rochester, NY/Etats-Unis (1 aut., 2 aut., 8 aut.); University of Rochester/Rochester, NY/Etats-Unis (3 aut., 4 aut.); Georgetown University/Washington, DC/Etats-Unis (5 aut.); University of Toronto/London, Ontario/Canada (6 aut.); Western University/London, Ontario/Canada (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2014; Vol. 82; No. 20; Pp. 1791-1797; Bibl. 23 ref.
LA :	Anglais
EA :	Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [¹²³\|] β-CIT SPECT scans were acquired. The percent change in [¹²³\|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [¹²³\|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.
CC :	002B17; 002B18D04B
FD :	Pathologie du système nerveux; Homme
ED :	Nervous system diseases; Human
SD :	Sistema nervioso patología; Hombre
LO :	INIST-6345.354000502741180070
ID :	14-0154166

Links to Exploration step

Pascal:14-0154166

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Longitudinal follow-up of SWEDD subjects in the PRECEPT Study</title>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation><inist:fA14 i1="02"><s1>University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation><inist:fA14 i1="02"><s1>University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation><inist:fA14 i1="03"><s1>Georgetown University</s1>
<s2>Washington, DC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>University of Toronto</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hyson, Chris" sort="Hyson, Chris" uniqKey="Hyson C" first="Chris" last="Hyson">Chris Hyson</name>
<affiliation><inist:fA14 i1="05"><s1>Western University</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0154166</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0154166 INIST</idno>
<idno type="RBID">Pascal:14-0154166</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000021</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Longitudinal follow-up of SWEDD subjects in the PRECEPT Study</title>
<author><name sortKey="Marek, Kenneth" sort="Marek, Kenneth" uniqKey="Marek K" first="Kenneth" last="Marek">Kenneth Marek</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Seibyl, John" sort="Seibyl, John" uniqKey="Seibyl J" first="John" last="Seibyl">John Seibyl</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Eberly, Shirley" sort="Eberly, Shirley" uniqKey="Eberly S" first="Shirley" last="Eberly">Shirley Eberly</name>
<affiliation><inist:fA14 i1="02"><s1>University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name>
<affiliation><inist:fA14 i1="02"><s1>University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Shoulson, Ira" sort="Shoulson, Ira" uniqKey="Shoulson I" first="Ira" last="Shoulson">Ira Shoulson</name>
<affiliation><inist:fA14 i1="03"><s1>Georgetown University</s1>
<s2>Washington, DC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation><inist:fA14 i1="04"><s1>University of Toronto</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hyson, Chris" sort="Hyson, Chris" uniqKey="Hyson C" first="Chris" last="Hyson">Chris Hyson</name>
<affiliation><inist:fA14 i1="05"><s1>Western University</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jennings, Danna" sort="Jennings, Danna" uniqKey="Jennings D" first="Danna" last="Jennings">Danna Jennings</name>
<affiliation><inist:fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neurology</title>
<title level="j" type="abbreviated">Neurology</title>
<idno type="ISSN">0028-3878</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>Nervous system diseases</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Pathologie du   système nerveux</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [<sup>123</sup>
|] β-CIT SPECT scans were acquired. The percent change in [<sup>123</sup>
|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [<sup>123</sup>
|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0028-3878</s0>
</fA01>
<fA02 i1="01"><s0>NEURAI</s0>
</fA02>
<fA03 i2="1"><s0>Neurology</s0>
</fA03>
<fA05><s2>82</s2>
</fA05>
<fA06><s2>20</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Longitudinal follow-up of SWEDD subjects in the PRECEPT Study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MAREK (Kenneth)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SEIBYL (John)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>EBERLY (Shirley)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>OAKES (David)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SHOULSON (Ira)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>LANG (Anthony E.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HYSON (Chris)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>JENNINGS (Danna)</s1>
</fA11>
<fA14 i1="01"><s1>Institute for Neurodegenerative Disorders</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Rochester</s1>
<s2>Rochester, NY</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Georgetown University</s1>
<s2>Washington, DC</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>University of Toronto</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Western University</s1>
<s2>London, Ontario</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>The Parkinson Study Group PRECEPT Investigators</s1>
<s3>INC</s3>
</fA17>
<fA20><s1>1791-1797</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>6345</s2>
<s5>354000502741180070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0154166</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neurology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [<sup>123</sup>
|] β-CIT SPECT scans were acquired. The percent change in [<sup>123</sup>
|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [<sup>123</sup>
|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B18D04B</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
<s5>09</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
<s5>09</s5>
</fC03>
<fN21><s1>195</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0154166 INIST</NO>
<ET>Longitudinal follow-up of SWEDD subjects in the PRECEPT Study</ET>
<AU>MAREK (Kenneth); SEIBYL (John); EBERLY (Shirley); OAKES (David); SHOULSON (Ira); LANG (Anthony E.); HYSON (Chris); JENNINGS (Danna)</AU>
<AF>Institute for Neurodegenerative Disorders/Rochester, NY/Etats-Unis (1 aut., 2 aut., 8 aut.); University of Rochester/Rochester, NY/Etats-Unis (3 aut., 4 aut.); Georgetown University/Washington, DC/Etats-Unis (5 aut.); University of Toronto/London, Ontario/Canada (6 aut.); Western University/London, Ontario/Canada (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Neurology; ISSN 0028-3878; Coden NEURAI; Etats-Unis; Da. 2014; Vol. 82; No. 20; Pp. 1791-1797; Bibl. 23 ref.</SO>
<LA>Anglais</LA>
<EA>Objective: To compare the clinical and imaging characteristics of those PRECEPT (Parkinson Research Examination of CEP-1347 Trial) subjects with a scan without evidence of dopaminergic deficit (SWEDD) to those with dopamine transporter (DAT) deficit scans at study baseline and during a 22-month follow-up. Methods: Baseline (n = 799) and 22-month follow-up (n = 701) [<sup>123</sup>
|] β-CIT SPECT scans were acquired. The percent change in [<sup>123</sup>
|] β-CIT striatal binding ratio, the percentage of subjects requiring dopaminergic therapy, the change in Unified Parkinson's Disease Rating Scale (UPDRS) score, and the PRECEPT Study investigators' diagnosis at study termination were compared between SWEDD and DAT deficit subjects. Results: SWEDD subjects (n = 91) compared with DAT deficit subjects (n = 708) showed reduced UPDRS score at baseline (18.7 [SD 8.5] vs 25.5 [SD 10.5], p < 0.05) and minimal change in both [<sup>123</sup>
|] β-CIT striatal binding ratio (-0.2% [SD 12.2] vs -8.5% [SD 11.9], p < 0.0001) and UPDRS score (0.5 [SD 6.9] vs 10.5 [SD 8.9], p < 0.0001) at follow-up assessments. At PRECEPT termination, the diagnosis by study investigators was changed from Parkinson disease (PD) to other disorders not associated with DAT deficit in 44% (95% confidence interval 34.2, 54.7) of SWEDD subjects compared with 3.6% (95% confidence interval 2.3, 5.1) of DAT deficit subjects. Conclusion: These results indicate that subjects identified as having a SWEDD, with DAT imaging within the normal range, have minimal evidence of clinical or imaging PD progression. These data strongly suggest that SWEDD subjects are unlikely to have idiopathic PD.</EA>
<CC>002B17; 002B18D04B</CC>
<FD>Pathologie du   système nerveux; Homme</FD>
<ED>Nervous system diseases; Human</ED>
<SD>Sistema nervioso patología; Hombre</SD>
<LO>INIST-6345.354000502741180070</LO>
<ID>14-0154166</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000021 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000021 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0154166
   |texte=   Longitudinal follow-up of SWEDD subjects in the PRECEPT Study
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri